To the Editor Whereas classic teaching highlights reduced infection risk, fewer hospitalizations, and lower total costs associated with hemodialysis (HD) that is initiated via arteriovenous fistula (AVF) vs hemodialysis catheter (HC), and whereas the National Kidney Foundation-Kidney Disease Outcomes Quality Initiative 1 first published practice guidelines regarding permanent HD access creation and maintenance in 1997, targeting a 50% or greater incidence rate for AVF, Malas et al 2 have demonstrated in a retrospective analysis of 510 000 patients with end-stage renal disease (ESRD) in the US Renal Data System database that 82.6% of these patients initiated HD via HC, 14.0% via AVF, and 3.4% via arteriovenous graft. Arteriovenous fistula use increased only minimally, from 12.2% in 2006 to 15.0% in 2010. 2 Furthermore, patients initiating HD with AVF had 35% lower mortality than those initiating HD with HC (adjusted hazard ratio, 0.65; 95% CI, 0.64-0.66; P < .001). 2 As a consequence, survival at 1 year was 78% in the HC group compared with 84% for the arteriovenous graft group and 89% for the AVF group (Wilcoxon P < .001). 2 Arteriovenous fistula use was associated with a 38% lower hazard of cardiovascular mortality (adjusted hazard ratio, 0.62; 95% CI, 0.61-0.64; P < .001) and with a 44% lower hazard of sepsis-related mortality (adjusted hazard ratio, 0.56; 95% CI, 0.53-0.59; P < .001). 2 The question therefore arises as to why, despite this evidence in support of AVF use at HD initiation, we in the United States have continued to have very low AVF rates at HD initiation despite the widespread implementation of Fistula-First programs. 1 Malas et al 2 had proffered some solutions to this problem, such as targeted pay incentives to enhance early nephrology referrals to surgeons for AVF creation and health insurance policy changes to cover for AVF creation procedures. 2 In 2010, I described, for the first time, the syndrome of rapidonset ESRD. 3 This is an acute-yet-irreversible type of ESRD following episodes of acute kidney injury among patients with chronic kidney disease. 3 Our experience suggests that the syndrome of rapid-onset ESRD could at least partly explain why we are unable to achieve higher AVF rates at HD initiation. 3,4 In a recent 13-year cohort analysis of patients with incident ESRD seen at the Mayo Clinic in Rochester, Minnesota, 149 of 1461 patients with ESRD (10.2%) demonstrated the features of the syndrome of rapid-onset ESRD. 4 Furthermore, of these 149 patients, 147 (98.7%) initiated HD with an HC. 4 Perhaps more "renoprevention" measures to reduce the incidence of acute kidney injury may be another solution to the high use of HCs for the care of patients with ESRD in the United States.
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